Arbutus Biopharma (ABUS) Total Liabilities (2010 - 2026)

Arbutus Biopharma has disclosed Total Liabilities across 17 years of filings, most recently posting $17.0 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $17.0 million, down 55.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.0 million (down 55.12% YoY), and the FY2025 annual result was $18.0 million, down 47.46% from the prior year.
• Total Liabilities came in at $17.0 million for Q1 2026 at Arbutus Biopharma, down from $18.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $71.0 million in Q1 2022 to a low of $17.0 million in Q1 2026.
• The 5-year median for Total Liabilities is $37.9 million (2025), against an average of $39.5 million.
• Across the five-year window, Total Liabilities soared 121.35% in 2022 and slumped 55.12% in 2026, its largest moves.
• Arbutus Biopharma's Total Liabilities stood at $58.6 million in 2022, then sank by 34.46% to $38.4 million in 2023, then declined by 10.53% to $34.3 million in 2024, then plunged by 47.46% to $18.0 million in 2025, then fell by 5.85% to $17.0 million in 2026.
• The last three Total Liabilities figures came in at $17.0 million (Q1 2026), $18.0 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.